3/12/21, “The Latest: US health officials warn of false positives,” AP
“The Food and Drug Administration issued the alert on Friday [March 13] for health facilities using Roche’s [PCR] cobas test for coronavirus and seasonal flu.”
………………………..
3/12/21, “FDA warns of potential false positive results with Roche Cobas rapid coronavirus, flu test,” Genomeweb via Modern Healthcare
“The US Food and Drug Administration released a letter on Friday warning clinical laboratory and point-of-care staff, as well as healthcare providers, that false positive results for Roche’s [PCR] test for SARS-CoV-2 and influenza A/B may occur….
Roche’s test received Emergency Use Authorization from the FDA in September [2020] for use in moderate- or high-complexity labs and at the point of care. The test uses nasal swabs to differentiate viral nucleic acid from SARS-CoV-2 and influenza A and B and can return results in 20 minutes….
The false positives for the Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, which is used on Roche’s [PCR] Cobas Liat system, could
be related to two different issues raised by Roche, the FDA said. One
is that the assay tubes might sporadically leak and cause an obstructed
optical path in the Cobas Liat analyzer, resulting in abnormal PCR growth curves. This could cause invalid or incorrect positives, specifically for influenza B tests….
The other issue is that abnormal PCR cycling in the reaction tubes could produce abnormal PCR growth curves, causing false positives. FDA
said the issue is sporadic and can be caused by hardware positioning,
volume movement, and curve interpretation. The problem can cause false positives for any and all analytes in the run.
In the letter, FDA recommended people who are using the test should “monitor for unexpected clusters of positive Flu B results” and repeat tests when two or three analytes are positive, because different results on the repeat test could signal abnormal PCR cycling.
If users expect either of the two issues to have happened, they should
stop using the system and contact Roche, FDA wrote. The agency added
that it is working with Roche to resolve the problems.
In an email, a Roche spokesperson said the company had recently identified “some erroneous results” with the test, specifically false positives,
particularly in the Type B flu test, that had occurred sporadically.
The spokesperson added that Roche is conducting an in-depth
investigation to understand the cause and determine next steps, and proactively reported the events to the FDA.”…
…………………………………………………
Added: AP article
March 12, 2021, “The Latest: US health officials warn of false positives,” AP
“U.S. health officials are warning health professionals about the risk of false positive results with a widely used [PCR] laboratory test for COVID-19 and flu.
The Food and Drug Administration issued the alert on Friday [March 13] for health facilities using Roche’s [PCR] cobas test for coronavirus and seasonal flu. The agency warned that problems with the test’s processing tubes could result in false diagnosis in people who are not actually infected.
Roche’s testing system is widely used to screen large batches of patient samples in hospitals and laboratories.
The FDA recommends health workers test samples multiple times to help assure accuracy. If the test delivers conflicting results it may indicate a problem and use should be discontinued, the agency says.”
___……………………
No comments:
Post a Comment